Dr. Lee on Defining Smoldering Multiple Myeloma

Partner | Cancer Centers | <b>SCCA</b>

Sarah S. Lee, MD, discusses definition criteria for smoldering multiple myeloma.

Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses definition criteria for smoldering multiple myeloma.

Laboratory findings, as well as bone marrow biopsy results, are used to make a diagnosis of smoldering multiple myeloma, Lee explains. The International Myeloma Working (IMW) Group recommends that all patients with suspected smoldering multiple myeloma undergo a PET-CT scan, a low-dose whole body CT scan, or an MRI of the whole body or spine.

Per the IMW Group criteria, patients with smoldering myeloma must have a serum monoclonal protein of at least 30 g/L or a urinary monoclonal protein of at least 500 mg/day and/or clonal bone marrow plasma cells of 10% to 60%, Lee says.

Additionally, patients must not have any myeloma-defining events or amyloidosis, Lee concludes.